- Conditions
- Asthma
- Interventions
- Albuterol Spiromax, ProAir HFA, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 1,406
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mesothelioma
- Interventions
- Magnesium Sulfate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Interventions
- BMN 110
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Oakland, California • Manhasset, New York
- Conditions
- Tibial Plateau Fractures
- Interventions
- Saline injection, Multimodal injections
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
- Interventions
- Selumetinib, Sirolimus
- Drug
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 2 more
- Conditions
- Postoperative Pain
- Interventions
- Q8003 (morphine sulfate and oxycodone hydrochloride), Morphine sulfate, Oxycodone HCl
- Drug
- Lead sponsor
- QRxPharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 1 more
- Conditions
- Solid Tumours
- Interventions
- selumetinib, itraconazole, fluconazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Pregnancy Related, Anemia, Iron Deficiency, Anemia of Pregnancy
- Interventions
- Ferumoxytol, Ferrous Sulfate
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- Quinine sulfate, Probenecid, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1988
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- dapsone gel, dapsone gel vehicle, sodium lauryl sulfate, Normal saline
- Drug
- Lead sponsor
- Almirall, S.A.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 237 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Interventions
- Selumetinib, Docetaxel, Placebo, Pegylated G-CSF
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
- Conditions
- Ovarian Cancer, Sarcoma
- Interventions
- cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, brachytherapy, intraoperative radiation therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Low Back Pain, Chronic Neck Pain
- Interventions
- Morphine, Duloxetine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
- Interventions
- Buprenorphine, Morphine Sulfate
- Drug
- Lead sponsor
- Pediatrix
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Anemia, Iron Deficiency, Delivery Complication
- Interventions
- Ferrous sulfate, Iron dextran
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
- Interventions
- Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Radiation Therapy, Thioguanine, Vincristine, Vincristine Sulfate
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 847 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 188
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- DMSA, Ca-EDTA, Magnesium Sulfate, Multivitamin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Osteoarthritis, Chronic Pain
- Interventions
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 547 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
- Conditions
- Cervical Cancer
- Interventions
- cisplatin, vincristine sulfate, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Bellflower, California • Los Angeles, California + 35 more
- Conditions
- Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS), Cardiac Amyloidosis
- Interventions
- 124I-evuzamitide
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Oakland, California • San Diego, California + 18 more
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
- Interventions
- nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium
- Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- HIV Infections
- Interventions
- Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 1,864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 51
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 30 more